[1]CurrentPatentAssignee:BETTAPHARMACEUTICALSCOLTD-WO2003/82830,2003,A1Locationinpatent:Page/Pagecolumn25-26
[1]Hu,Shaojing;Xie,Guojian;Zhang,DonX.;Davis,Charles;Long,Wei;Hu,Yunyan;Wang,Fei;Kang,Xinshan;Tan,Fenlai;Ding,Lieming;Wang,Yinxiang[BioorganicandMedicinalChemistryLetters,2012,vol.22,#19,p.6301-6305]
[2]Mao,Longfei;Sun,Ge;Zhao,Jie;Xu,Guiqing;Yuan,Miaomiao;Li,Yue-Ming[BioorganicChemistry,2020,vol.105]
[3]CurrentPatentAssignee:NANKAIUNIVERSITY-CN111909163,2020,ALocationinpatent:Paragraph0044-0046
[4]Chen,Xiaojie;Mao,Long-Fei;Tian,Siqi;Tian,Xueli;Meng,Xueqiong;Wang,Mu-Kuo;Xu,Weifeng;Li,Yue-Ming;Liu,Kangdong;Dong,Zigang[FrontiersinPharmacology,2022,vol.13]
[1]CurrentPatentAssignee:BETAPHARMAINC-WO2014/28914,2014,A1Locationinpatent:Page/Pagecolumn32
[2]CurrentPatentAssignee:Liu,Wenpei;Wu,Zhangxing;Feng,Dezhe-CN106188072,2016,ALocationinpatent:Paragraph0203;0204;0205
[1]CurrentPatentAssignee:BETTAPHARMACEUTICALSCOLTD-EP2796461,2014,A1Locationinpatent:Paragraph0057-0059;0097-0103
[2]CurrentPatentAssignee:BETTAPHARMACEUTICALSCOLTD-US2014/343283,2014,A1Locationinpatent:Paragraph0130-0136
[3]CurrentPatentAssignee:BETTAPHARMACEUTICALSCOLTD-TWI612039,2018,BLocationinpatent:Paragraph0078;00119;00121;00123;00124;00125
[1]CurrentPatentAssignee:BETTAPHARMACEUTICALSCOLTD-WO2014/198210,2014,A1Locationinpatent:Page/Pagecolumn10;11
[2]CurrentPatentAssignee:BETTAPHARMACEUTICALSCOLTD-WO2014/198212,2014,A1Locationinpatent:Page/Pagecolumn11;12;13
Title: Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.
Journal: Toxicology and applied pharmacology 20161101
Title: Investigation on the protein-binding properties of icotinib by spectroscopic and molecular modeling method.
Journal: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20160515
Title: Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Journal: Future oncology (London, England) 20150101
Title: Icotinib: activity and clinical application in Chinese patients with lung cancer.
Journal: Expert opinion on pharmacotherapy 20140401
Title: Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20121001
Title: Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Journal: Oncology reports 20120601
Title: [Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120520
Title: Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Journal: Lung cancer (Amsterdam, Netherlands) 20120501
Title: New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.
Journal: Tumori 20120101
Title: Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry.
Journal: Rapid communications in mass spectrometry : RCM 20110815
Title: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Journal: Lung cancer (Amsterdam, Netherlands) 20110801
Title: Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
Journal: Chinese medical journal 20110705
Title: Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Journal: Chinese medical journal 20110101
Title: Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091115
Title: Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry.
Journal: Rapid communications in mass spectrometry : RCM 20080701
Title: Tan F, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76(2):177-82.
